Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit current status and future prospects (2018) Antoni Torres

Description

This review examines the evidence regarding inhaled amikacin for severe Gram-negative pulmonary infections in the ICU, particularly following unconvincing results from recent randomized clinical trials. It reappraises the therapeutic strategy, discusses potential factors for negative findings, and suggests ways to promote translational research and improve the design of future clinical trials in critical care medicine.